OncoMatch/Clinical Trials/NCT06474676
T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
Is NCT06474676 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cyclophosphamide and T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy for metastatic soft-tissue sarcoma.
Treatment: Cyclophosphamide · T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy — To find a recommended dose of attIL2-TIL cell therapy that can be given to participant with either relapsed or metastatic sarcomas (has come back or spread to other parts of the body, respectively). To further test the dose found in Part A to see if it can help to control liposarcoma growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Prior therapy
Lab requirements
Blood counts
absolute neutrophil count (anc) > 1 k/ul, hemoglobin > 9 g/dl, platelets > 100 k/mm3
Kidney function
serum creatinine ≤ 2 mg/dl or creatinine clearance > 50 ml/min
Liver function
ast ≤ 1.5 x uln, alt ≤ 1.5 x uln, bilirubin ≤ 1.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify